KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting

Key facts

Sponsor

Kumquat Biosciences Inc.

Intervention

KQB198(drug)

Enrollment

46 enrolled

Eligibility

18 years · All sexes

Timeline

2026 – 2028

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Gastrointestinal stromal tumor

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT07171203
  Neoadjuvant Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor
  University of California, San Diego
• RECRUITINGPHASE2NCT07434843
  PH 2 Pemigatinib in SDH-deficient GIST
  Dana-Farber Cancer Institute
• ENROLLING BY INVITATIONPHASE2NCT07550582
  Mesenteric Vascular Preconditioning Combined With Laparoscopic and Endoscopic Cooperative Surgery for Submucosal Tumor at the Gastroesophageal Junction
  Peking University People's Hospital
• RECRUITINGNANCT07405125
  Safety of Robotic Surgery for GISTs at Special Anatomic Sites
  The First Affiliated Hospital with Nanjing Medical University
• RECRUITINGPHASE3NCT07218926
  A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
  GlaxoSmithKline
• RECRUITINGPHASE1, PHASE2NCT07096609
  Lenvatinib After Progression on Imatinib, Sunitinib, and Regorafenib for GIST Patients
  Asan Medical Center
• RECRUITINGPHASE2NCT07559864
  Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment
  Jian Li
• RECRUITINGNCT07522762
  Long-term Survivorship Challenges of Advanced/Metastatic GIST Patients Responding to Tyrosine Kinase Inhibitor Treatment: an Observational Study
  The Netherlands Cancer Institute

See all trials for Gastrointestinal stromal tumor →